

OneAscent SMID Growth

Fact Sheet: June 30th, 2025

INVESTMENT APPROACH

Combining OneAscent's values-based investing approach and Eventide's portfolio management insight, the SMID Growth strategy is actively managed and may be appropriate for investors interested in market exposure with less correlation to standard indices

The strategy invests primarily in U.S. equities and typically includes less than 10% foreign equity exposure. The size-weighted, average market cap for the strategy will typically fall between \$2-20 billion USD, with most portfolio companies falling in this range.

Stock selection is driven by Eventide's fundamental research and values-based criteria. Investment decisions may also take into account overall market conditions and trading volumes.

INVESTMENT OBJECTIVE

Long-term capital appreciation

TARGET HOLDINGS

BENCHMARK

Morningstar US SMID Growth TR Index

INVESTMENT MINIMUM \$50,000

MANAGEMENT FEE

INVESTMENT PROCESS

- **Identify companies** with (1) strong fundamentals, (2) that create value for stakeholders, and (3) trade at attractive valuations.
- Establish an investment case based on fundamental analysis of the company's products or services, the industry in which it operates, sustainable competitive advantages, management team, and financials as well as research on how the company creates value for customers, employees, society, the environment, and local communities. Valuation analysis is then performed to establish a price target as well as upside and downside valuation.
- Evaluate the health of the market by utilizing a three-legged stool approach to assess leading indicators, valuation measures, and investor sentiment.
- Construct the portfolio with appropriate industry and sector weightings informed by the level of macro risk. Determine position sizing based on conviction level and risk/reward profile.
- Actively monitor holdings to ensure that the investment thesis remains intact.

MANAGED BY



Finny Kuruvilla, MD, PhDPortfolio Manager

Finny Kuruvilla serves as Chief Investment Officer and Portfolio Manager for Eventide Asset Management. Dr. Kuruvilla has a unique background in healthcare, statistics, and investing.

Eventide Asset Management is an independently registered third party investment adviser and is not affiliated with OneAscent Investment Solutions.



TRAILING RETURNS

| | 3 Month | YTD | 1 Year | 2 Year | 3 Year | 5 Year | Since Inception |
|-----------------------------------|---------|------|--------|--------|--------|--------|--------------------|
| OneAscent SMID Growth | 16.73 | 8.13 | 14.91 | 7.89 | 12.50 | 7.73 | 12.70 |
| Morningstar US SMID Growth TR USD | 15.28 | 7.47 | 20.87 | 16.87 | 17.59 | 9.65 | 12.32 |

OneAscent Investment Solutions LLC ("OneAscent") was formed in March 2017, and manages a variety of equity, income and balanced asset strategies for client accounts. OneAscent is an investment adviser registered with the United States Securities and Exchange Commission. Registration as an investment adviser does not imply any certain degree of skill or training. OneAscent's Form ADV Part 2A is available on its website, www.oneascent.com, or the SEC's website, at www.adviserinfo.sec.gov, or by contacting the firm. Please consult OneAscent's Form ADV Part 2A for information regarding account minimums and fees.

Inception Date: 3/15/2017

Performance information for the attached strategy is calculated using model performance and is based on the portfolio allocation data since inception. The strategy has not materially changed since inception. Model performance is net of any fees on underlying mutual funds and ETFs and a management fee of 0.60% applied annually to the entire strategy. The model performance does not include any overlay fees, brokerage fees, or commissions. OneAscent is unaware of what the exact amounts of these fees will be on a client by client basis, and cannot reasonably estimate their costs. Performance for periods longer than a year has been annualized. Model performance means that while actual client accounts will be managed as closely to the model as possible, the performance reported is for the targeted portfolio allocations for the strategy and not a composite of actual client accounts. Accordingly, individual client performance may vary according to various factors, including fee arrangements, withdrawals, contributions, and tax considerations, among other factors. The above stated portfolio performance is gross of any third pary financial advisor's fees. A client's returns will be reduced by the advisory fee if incurred in the management of the its account. For example, the deduction of a 1% advisory fee over a 10-year period would reduce a 10% gross return to an 8.9% net return. OneAscent does not control the fee amounts charged by recommending advisers. A complete listing of all trades in the model, as well as a full description of the model/strategy are available upon request.


OneAscent

INVESTMENTS

OneAscent SMID Growth

Fact Sheet: June 30th, 2025

SECTOR ALLOCATION



TOP HOLDINGS

| Company | Ticker | Weight % |
|---|--------|----------|
| Verona Pharma PLC ADR | VRNA | 6.25 |
| Guardant Health Inc | GH | 4.27 |
| Toast Inc Class A | TOST | 3.74 |
| Xometry Inc Ordinary Shares - Class A | XMTR | 3.48 |
| Trane Technologies PLC Class A | TT | 2.69 |
| SPDR® Blmbg 1-3 Mth T-Bill ETF | BIL | 2.68 |
| Mirum Pharmaceuticals Inc | MIRM | 2.56 |
| iRhythm Technologies Inc | IRTC | 2.47 |
| Vistra Corp | VST | 2.37 |
| Old Dominion Freight Line Inc Ordinary Shares | ODFL | 2.23 |

MARKET RISK

| | Std Dev | Alpha | Beta | R2 | Sharpe |
|-----------------------------------|---------|-------|------|--------|--------|
| OneAscent SMID Growth | 22.09 | 0.46 | 1.03 | 91.77 | 0.55 |
| Morningstar US SMID Growth TR USD | 20.63 | 0.00 | 1.00 | 100.00 | 0.55 |

ANNUAL RETURNS

| | 2017* | 2018 | 2019 | 2020 |
|-----------------------------------|-------|--------|-------|-------|
| OneAscent SMID Growth | 20.21 | -1.95 | 40.49 | 50.17 |
| Morningstar US SMID Growth TR USD | 16.71 | -3.87 | 34.04 | 45.67 |
| | 2021 | 2022 | 2023 | 2024 |
| OneAscent SMID Growth | 12.71 | -32.05 | 28.32 | 1.97 |
| Morningstar US SMID Growth TR USD | 10.90 | -32.61 | 25.70 | 18.51 |

From inception through 6/30/2024, the benchmark for this strategy was the Russell 2500 Growth index. As of that date, this index was no longer available for our purposes. As of June 30, 2024, this strategy's benchmark will be the Morningstar US SMID Growth TR Index, which we believe will as closely approximate the makeup of this strategy as the Russell 2500 Growth index did. Indices are reported to give a point of comparison only. An investor may not invest directly in an index. Benchmark data is provided by Morningstar and has not been independently verified.

The strategy is not necessarily appropriate for any particular client or investor. Accordingly, any reader of the attached description should not interpret the attached as investment advice. All investments bear a risk of loss, including the loss of principal that the investor should be prepared to bear. The use of any chart or graph in the attached is not intended to be viewed as a singular aid in determining investment strategy. Such visual aids are instead intended as a complement to other data, and like such other data, should be considered in light of consultations with professional investment tax and legal advisors. Past performance may not be indicative of future results. No current or prospective client should assume that the future performance of any specific investment, investment strategies (including investments and/or investment strategies recommended by the adviser), will be equal to past performance levels. Indices are reported to give a point of comparison only. An investor may not invest directly in an index. Different types of investments involve varying degrees of risk, and there can be no assurance that any specific investment will either be suitable or profitable for a client's investment portfolio.

*Partial period return (March 16, 2017 to December 31, 2017).